Literature DB >> 28101144

Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation.

Claudio Corallo1, Maurizio Cutolo2, Nila Volpi3, Daniela Franci3, Margherita Aglianò3, Antonio Montella3, Chiara Chirico3, Stefano Gonnelli3, Ranuccio Nuti3, Nicola Giordano3.   

Abstract

OBJECTIVES: The objective of this study was to identify specific histopathological features of skeletal muscle involvement in systemic sclerosis (SSc) patients.
METHODS: A total of 35 out of 112 SSc-patients (32%, including 81% female and 68% diffuse scleroderma) presenting clinical, biological and electromyographic (EMG) features of muscle weakness, were included. Patients underwent vastus lateralis biopsy, assessed for individual pathologic features including fibrosis [type I collagen (Coll-I), transforming growth factor β (TGF-β)], microangiopathy [cluster of differentiation 31 (CD31), pro-angiogenic vascular endothelial growth factor A (VEGF-A), anti-angiogenic VEGF-A165b], immune/ inflammatory response [CD4, CD8, CD20, human leucocyte antigens ABC (HLA-ABC)], and membranolytic attack complex (MAC). SSc biopsies were compared with biopsies of (n = 35) idiopathic inflammatory myopathies (IIMs) and to (n = 35) noninflammatory myopathies (NIMs). Ultrastructural abnormalities of SSc myopathy were also analyzed by transmission electron microscopy (TEM).
RESULTS: Fibrosis in SSc myopathy (81%) is higher compared with IIM (32%, p < 0.05) and with NIM (18%, p < 0.05). Vascular involvement is dominant in SSc muscle (92%), and in IIM (78%) compared with NIM (21%, p < 0.05). In particular, CD31 shows loss of endomysial vessels in SSc myopathy compared with IIM (p < 0.05) and with NIM (p < 0.01). VEGF-A is downregulated in SSc myopathy compared with IIM (p < 0.05) and NIM (p < 0.05). Conversely, VEGF-A165b is upregulated in SSc myopathy. The SSc immune/inflammatory response suggested humoral process with majority (85%) HLA-ABC fibral neoexpression and complement deposits on endomysial capillaries MAC, compared with IIM (p < 0.05), characterized by CD4+/CD8+/B-cell infiltrate, and NIM (p < 0.05). TEM analysis showed SSc vascular alterations consisting of thickening and lamination of basement membrane and endothelial cell 'swelling' coupled to endomysial/perimysial fibrosis.
CONCLUSIONS: Fibrosis, microangiopathy and humoral immunity are predominant in SSc myopathy, even if it is difficult to identify specific histopathological hallmarks of muscle involvement in SSc, since they could be present also in other (IIM/NIM) myopathies.

Entities:  

Keywords:  fibrosis; histopathology; microangiopathy; myopathy; systemic sclerosis

Year:  2016        PMID: 28101144      PMCID: PMC5228640          DOI: 10.1177/1759720X16671928

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  19 in total

1.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

Review 2.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

3.  Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.

Authors:  Yves Troyanov; Ira N Targoff; Jean-Luc Tremblay; Jean-Richard Goulet; Yves Raymond; Jean-Luc Senécal
Journal:  Medicine (Baltimore)       Date:  2005-07       Impact factor: 1.889

4.  Progressive systemic sclerosis: autoimmune arteriopathy.

Authors:  D J Evans; S J Cashman; M Walport
Journal:  Lancet       Date:  1987-02-28       Impact factor: 79.321

5.  Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association.

Authors:  W P Follansbee; T R Zerbe; T A Medsger
Journal:  Am Heart J       Date:  1993-01       Impact factor: 4.749

6.  Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness.

Authors:  Julie J Paik; Fredrick M Wigley; Thomas E Lloyd; Andrea M Corse; Livia Casciola-Rosen; Ami A Shah; Francesco Boin; Laura K Hummers; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

Review 7.  Systemic sclerosis-associated myopathy.

Authors:  Brigitte Ranque; François-Jérôme Authier; Alice Berezne; Loïc Guillevin; Luc Mouthon
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

Review 8.  TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology.

Authors:  Masato Morikawa; Rik Derynck; Kohei Miyazono
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-05-02       Impact factor: 10.005

Review 9.  Musculoskeletal Manifestations of Systemic Sclerosis.

Authors:  Kathleen B Morrisroe; Mandana Nikpour; Susanna M Proudman
Journal:  Rheum Dis Clin North Am       Date:  2015-05-26       Impact factor: 2.670

10.  Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling within Lesional Scleroderma Skin.

Authors:  Joanna Nikitorowicz-Buniak; Christopher P Denton; David Abraham; Richard Stratton
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

View more
  7 in total

1.  Body composition and bone status in relation to microvascular damage in systemic sclerosis patients.

Authors:  V Smith; M Cutolo; S Paolino; E Gotelli; F Goegan; A Casabella; G Ferrari; M Patane; M Albertelli; F Gatto; C Pizzorni; F Cattelan; A Sulli
Journal:  J Endocrinol Invest       Date:  2020-05-24       Impact factor: 4.256

2.  The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus.

Authors:  John D Pauling; Sarah Skeoch; Julie J Paik
Journal:  Indian J Rheumatol       Date:  2021-01-18

Review 3.  Inflammatory myopathies overlapping with systemic sclerosis: a systematic review.

Authors:  Jucier Gonçalves Júnior; Naoki Mugii; Pleiades Tiharu Inaoka; Percival Degrava Sampaio-Barros; Samuel Katsuyuki Shinjo
Journal:  Clin Rheumatol       Date:  2022-02-27       Impact factor: 2.980

4.  Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology.

Authors:  Elise Siegert; Akinori Uruha; Carsten Dittmayer; Werner Stenzel; Hans-Hilmar Goebel; Corinna Preuße; Vincent Casteleyn; Felix Kleefeld; Rieke Alten; Gerd R Burmester; Udo Schneider; Jakob Höppner; Kathrin Hahn
Journal:  Acta Neuropathol       Date:  2021-04-17       Impact factor: 17.088

Review 5.  The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.

Authors:  Ioana Bratoiu; Alexandra Maria Burlui; Anca Cardoneanu; Luana Andreea Macovei; Patricia Richter; Gabriela Rusu-Zota; Ciprian Rezus; Minerva Codruta Badescu; Andreea Szalontay; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

Review 6.  Idiopathic inflammatory myopathies overlapping with systemic diseases.

Authors:  Sébastien Lepreux; Johannes A Hainfellner; Anne Vital
Journal:  Clin Neuropathol       Date:  2018 Jan/Feb       Impact factor: 1.368

7.  Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies.

Authors:  Océane Landon-Cardinal; Alexandra Baril-Dionne; Sabrina Hoa; Alain Meyer; Valérie Leclair; Josiane Bourré-Tessier; Anne-Marie Mansour; Farah Zarka; Jean-Paul Makhzoum; Jessica Nehme; Eric Rich; Jean-Richard Goulet; Tamara Grodzicky; Martial Koenig; France Joyal; Isabelle Richard; Marie Hudson; Ira Targoff; Minoru Satoh; Marvin J Fritzler; Yves Troyanov; Jean-Luc Senécal
Journal:  RMD Open       Date:  2020-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.